A new pan-cancer study has uncovered a shared vulnerability across multiple aggressive cancers and sheds light on the role that BRCA1-associated protein 1 (BAP1) plays in recognizing DNA damage. Researchers from Duke-National University of Singapore (NUS) Medical School in Singapore discovered that the loss of BAP1 – a mutation found in mesothelioma, cholangiocarcinoma, renal cell carcinoma and uveal melanoma – creates a specific defect in how cancer cells recognize and repair DNA damage.
Gilead Sciences is stepping deeper into synthetic lethality, licensing a clinic-ready MAT2A (methionine adenosyltransferase 2a) inhibitor from Suzhou, China-based Genhouse Bio Co. Ltd. in a deal worth up to $1.53 billion.
Gilead Sciences is stepping deeper into synthetic lethality, licensing a clinic-ready MAT2A (methionine adenosyltransferase 2a) inhibitor from Suzhou, China-based Genhouse Bio Co. Ltd. in a deal worth up to $1.53 billion.
GSK plc said in paperwork filed with the U.S. SEC that the potentially whopping deal inked in the summer of 2020 with Ideaya Biosciences Inc. has gone down the tubes. The two firms were collaborating on three of Ideaya’s synthetic lethality programs, MAT2A (methionine adenosyltransferase 2a), Pol Theta (polymerase theta) and Werner Helicase.
GSK plc said in paperwork filed with the U.S. SEC that the potentially whopping deal inked in the summer of 2020 with Ideaya Biosciences Inc. has gone down the tubes.
In a recent study published in Nature Genetics, a team of scientists used CRISPR-Cas9 gene editing to systematically analyze genetic weaknesses in uveal melanoma cells and comprehensively map monogenic and digenic dependencies.
Synthetic lethality specialist Tessellate Bio NV has closed its first deal, agreeing to a €500 million-plus (US$570 million) research and license agreement with Boehringer Ingelheim GmbH, to develop small molecules targeting tumors that depend on alternative lengthening of telomeres (ALT) for their growth.
It was a mixed day for Daewoong Pharmaceutical Co. Ltd., which disclosed separately on March 28 both the termination of a $336 million licensing deal with CS Pharmaceuticals Ltd. and upbeat plans to unveil three new oncology assets at the upcoming American Association for Cancer Research in April.
It was a mixed day for Daewoong Pharmaceutical Co. Ltd., which disclosed separately on March 28 both the termination of a $336 million licensing deal with CS Pharmaceuticals Ltd. and upbeat plans to unveil three new oncology assets at the upcoming American Association for Cancer Research in April.
Researchers from Tango Therapeutics Inc. have unveiled DNA ligase 1 (LIG1) as a potential new therapeutic target for synthetic lethality in BRCA1-mutant cancers after CRISPR/Cas9 screening.
